# SAM #HT941027N0014

DHA sole-source requirement for QuidelOrtho VITROS chemistry/immunology analyzers, reagents, and support

**Buyer:** Defense Health Agency
**Posted:** November 19, 2026
**Respond By:** December 03, 2026
**Identifier:** HT941027N0014
**NAICS:** 325413

DHA plans a sole-source, five-year laboratory analyzer and reagent requirement for Brian D. Allgood Army Community Hospital in South Korea.
- **Agency and customer:** Defense Health Agency Contracting Activity, Healthcare Contracting Division–San Diego, Echo Branch; Brian D. Allgood Army Community Hospital.
- **Intended source and OEM:** Ortho Clinical Diagnostics Singapore Pte. Ltd., Korea Branch, a division of QuidelOrtho Corporation. The notice identifies QuidelOrtho VITROS as the required technology.
- **Equipment and requirements:** VITROS chemistry/immunology analyzer system; analyzer quantity is not specified. Each analyzer must run both chemistry and immunology assays, use 100% waterless dry-slide technology, need no facility water, plumbing, or drains, and provide redundancy for continuous operation.
- **Reagents:** Reagents for 65 assay types, with estimated test volumes for a six-month base period and four 12-month option periods. Reagent-pack quantities are not specified; estimated test counts are listed in the product line items.
- **Included support:** Delivery, installation, training, calibrators, standards, reagents and reagent packs, quality-control materials, preventive and unscheduled maintenance, initial method validation under CLSI guidelines, and analyzer removal at contract end. Displays and supporting literature must be in English; the contractor must support the complete system, including parts, equipment, and supplies.
- **Competition:** This is a notice of intent to award sole source, not a request for competitive quotes. Interested parties may submit a capability statement challenging the sole-source basis.

### Description

<div>
  <p><strong>Notice of Intent to Sole Source</strong><br />HT941027N0014</p>

  <p><strong>THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE PURCHASE ORDER CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES.</strong></p>

  <p>The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – San Diego (HCD-SD), Echo Branch intends to award a firm fixed price five (5)-Year Purchase order RFO 12.102 (b) for acquisitions valued over the SAT, only one source being available to meet the Government’s needs, to:</p>

  <p>ORTHO CLINICAL DIAGNOSTICS SINGAPORE PTE LTD, KOREA BRANCH<br />
  366 HANGANG-DAERO<br />
  YONGSAN-GU, SEOUL, 04323 SOUTH KOREA<br />
  UEI: JNSJRDQQH2J6<br />
  CAGE: 767DF</p>

  <p>The North American Industry Classification System (NAICS) code for this requirement is 325413 - Pharmaceutical Preparation Manufacturing; the business size standard is 1,250 (in number of employees). The Product Service Code (PSC) is 6550 – Invitro Diagnostics Substances Reagents.</p>

  <p><strong>Requirement Overview</strong></p>
  <p>The objective of this sole source award is to procure Chemistry/Immunology Reagents with Analyzer for Brian D. Allgood Army Community Hospital, South Korea for the Department of Pathology.</p>
  <p>The contractor-furnished chemistry and immunology analyzers shall be capable of providing complete chemistry and immunochemistry testing. The entire analyzer system shall be serviced and supplied through a single Contractor awarded the contract, including all parts, equipment, and supplies not manufactured, provided, or serviced directly by the Contractor.</p>

  <p>The system shall provide redundancy to ensure continuous operations. Each analyzer shall have the capacity to perform both chemistry and immunology assays. The Contractor shall provide the system, training, supplies, reagents, unscheduled maintenance, and preventive maintenance. All equipment displays and supporting literature shall be in English.</p>

  <p>The Contractor shall include delivery, installation, all calibrators and standards, reagents and reagent packs, and quality-control materials necessary to perform the specified assays. The Contractor shall also perform initial method validations in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. The Contractor shall remove the analyzers upon contract termination.</p>

  <p><strong>Rationale Justifying Sole Source</strong></p>
  <p>Ortho Clinical Diagnostics Singapore Pte. Ltd., Korea Branch, a division of QuidelOrtho Corporation, is the sole manufacturer capable of providing clinical chemistry and integrated chemistry/immunoassay analyzers that meet the Government’s test-volume requirements without requiring a facility water supply.</p>

  <p>The Defense Health Agency requires analyzers that use 100 percent waterless, dry-slide technology. These sites cannot receive reagent-grade water into the facility for safe, quality laboratory testing and are not approved by the state to discharge biohazardous waste into any drain. This technology is unique to QuidelOrtho’s VITROS® line of analyzers and is essential to meeting the agency’s operational and mission requirements for the following reasons:</p>

  <p><strong>Infrastructure Independence:</strong> VITROS dry-slide technology eliminates the need for water, plumbing, and drains. This is a critical advantage in military healthcare environments, where logistical footprints must be minimized. It ensures operational continuity and significantly reduces infrastructure dependencies.</p>

  <p><strong>Enhanced Quality and Reliability:</strong> The system uses disposable tips for each sample, eliminating the risk of sample-to-sample carryover and reagent-to-reagent contamination that can occur in traditional wet-chemistry systems. This supports the accuracy and reliability of test results for patient care, particularly for high-acuity, time-sensitive assays.</p>

  <p>For example, emergency physicians rely on rapid, accurate first-run results for high-sensitivity troponin to triage potential heart attacks; procalcitonin and lactic acid to diagnose life-threatening sepsis; and potassium levels to treat sudden acute renal or metabolic failure. In these life-threatening situations, a false or contaminated initial result can delay critical medical intervention. The dry-slide technology’s elimination of sample carryover helps ensure that providers can rely on the initial result when time is of the essence.</p>

  <p><strong>Laboratory Productivity:</strong> Reagents are self-contained in a dry-slide format that provides calibration stability of up to six months for most assays. This extended calibration interval substantially reduces the time and labor associated with daily calibration and quality-control procedures while also reducing reagent waste.systems. This ensures the highest accuracy and reliability of test results for patient care, which is absolutely critical for high-acuity, time-sensitive assays. For example, emergency physicians rely on rapid, flawless first-time results for high sensitivity troponin to triage imminent heart attacks, procalcitonin and lactic acid to diagnose life-threatening sepsis, and potassium levels to treat sudden acute renal or metabolic failure. In these life-or-death scenarios, a false or contaminated first read delays vital medical interventions; the dry-slide technology's elimination of sample carryover ensures providers can trust the initial result when time is of the essence. Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides up to a six-month calibration stability for most assays. This extended frequency drastically reduces the time and labor spent on daily calibration and quality control procedures while decreasing reagent waste.</p>

  <p><strong>Product List</strong></p>
  <p><strong>Chemistry/Immunology Annual Test Count</strong></p>
  <p>Test | Base Year | 6-Month | Option Year I | Option Year II | Option Year III | Option Year IV</p>
  <ol>
    <li>ACETAMINOPHEN — 1,541 | 1,731 | 1,783 | 1,836 | 1,891</li>
    <li>ALBUMIN — 9,202 | 17,513 | 18,038 | 18,579 | 19,136</li>
    <li>ALANINE AMINOTRANSFERASE — 9,209 | 17,529 | 18,055 | 18,597 | 19,155</li>
    <li>ALKALINE PHOSPHATASE — 9,285 | 17,684 | 18,215 | 18,762 | 19,325</li>
    <li>AMYLASE — 1,470 | 1,586 | 1,634 | 1,683 | 1,734</li>
    <li>ASPARTATE AMINOTRANSFERASE — 9,914 | 18,980 | 19,549 | 20,136 | 20,740</li>
    <li>BILIRUBIN TOTAL — 9,581 | 18,295 | 18,844 | 19,409 | 19,991</li>
    <li>BILIRUBIN DIRECT — 1,343 | 2,088 | 2,151 | 2,216 | 2,283</li>
    <li>BILIRUBIN CONJUGATED — 662 | 1,003 | 1,033 | 1,064 | 1,096</li>
    <li>BILIRUBIN UNCONJUGATED — 662 | 1,003 | 1,033 | 1,064 | 1,096</li>
    <li>BILIRUBIN NEONATAL — 85 | 132 | 136 | 140 | 144</li>
    <li>CALCIUM — 9,642 | 18,420 | 18,973 | 19,542 | 20,128</li>
    <li>CARBON DIOXIDE — 9,626 | 18,387 | 18,939 | 19,507 | 20,092</li>
    <li>CHLORIDE — 9,771 | 18,686 | 19,247 | 19,824 | 20,419</li>
    <li>CHOLESTEROL TOTAL — 4,951 | 8,757 | 9,020 | 9,291 | 9,570</li>
    <li>CK-MB — 1,992 | 2,660 | 2,740 | 2,822 | 2,907</li>
    <li>C-REACTIVE PROTEIN — 2,349 | 3,396 | 3,498 | 3,603 | 3,711</li>
    <li>CREATININE — 10,084 | 19,360 | 19,941 | 20,539 | 21,155</li>
    <li>CREATININE, RANDOM URINE — 206 | 396 | 408 | 420 | 433</li>
    <li>CREATINE KINASE — 1,993 | 2,663 | 2,743 | 2,825 | 2,910</li>
    <li>ETHANOL — 2,674 | 4,065 | 4,187 | 4,313 | 4,442</li>
    <li>G-GLUTAMYL TRANSFERASE — 2,195 | 3,079 | 3,171 | 3,266 | 3,364</li>
    <li>GENTAMICIN PEAK — 834 | 579 | 596 | 614 | 632</li>
    <li>GENTAMICIN TROUGH — 222 | 154 | 159 | 164 | 169</li>
    <li>GLUCOSE — 10,228 | 19,784 | 20,378 | 20,989 | 21,619</li>
    <li>GLUCOSE 1ST — 46 | 89 | 92 | 95 | 98</li>
    <li>GLUCOSE 2ND — 46 | 89 | 92 | 95 | 98</li>
    <li>GLUCOSE 3RD — 46 | 89 | 92 | 95 | 98</li>
    <li>GLUCOSE POSTPRANDIAL — 3 | 4 | 4 | 4 | 4</li>
    <li>GLUCOSE POST 50G GLUCOLA 1H — 149 | 288 | 297 | 306 | 315</li>
    <li>GLUCOSE POST 75G GLUCOLA 2H — 12 | 23 | 24 | 25 | 26</li>
    <li>GLUCOSE FASTING — 918 | 1,775 | 1,828 | 1,883 | 1,940</li>
    <li>GLUCOSE CSF — 23 | 44 | 45 | 46 | 47</li>
    <li>HDL CHOLESTEROL — 4,879 | 8,609 | 8,867 | 9,133 | 9,407</li>
    <li>IRON — 1,465 | 1,575 | 1,622 | 1,671 | 1,721</li>
    <li>LACTATE — 1,647 | 1,951 | 2,010 | 2,070 | 2,132</li>
    <li>LACTATE DEHYDROGENASE — 1,476 | 1,598 | 1,646 | 1,695 | 1,746</li>
    <li>LIPASE — 2,637 | 3,990 | 4,110 | 4,233 | 4,360</li>
    <li>MAGNESIUM — 2,103 | 2,889 | 2,976 | 3,065 | 3,157</li>
    <li>PHOSPHORUS — 1,823 | 2,312 | 2,381 | 2,452 | 2,526</li>
    <li>POTASSIUM — 10,047 | 19,254 | 19,832 | 20,427 | 21,040</li>
    <li>PROTEIN — 9,075 | 17,253 | 17,771 | 18,304 | 18,853</li>
    <li>PROTEIN CSF — 847 | 303 | 312 | 321 | 331</li>
    <li>PROTEIN, RANDOM URINE — 1,184 | 996 | 1,026 | 1,057 | 1,089</li>
    <li>SALICYLATES — 1,520 | 1,689 | 1,740 | 1,792 | 1,846</li>
    <li>SODIUM — 10,568 | 20,327 | 20,937 | 21,565 | 22,212</li>
    <li>TRIGLYCERIDE — 4,983 | 8,822 | 9,087 | 9,360 | 9,641</li>
    <li>UREA NITROGEN — 9,808 | 18,761 | 19,324 | 19,904 | 20,501</li>
    <li>URIC ACID — 1,556 | 1,762 | 1,815 | 1,870 | 1,926</li>
    <li>VANCOMYCIN PEAK — 574 | 446 | 459 | 473 | 487</li>
    <li>VANCOMYCIN TROUGH — 551 | 429 | 442 | 455 | 469</li>
    <li>HCG QN — 2,628 | 3,972 | 4,091 | 4,214 | 4,340</li>
    <li>THYROTROPIN — 5,327 | 9,531 | 9,817 | 10,112 | 10,415</li>
    <li>T4 FREE — 2,318 | 3,332 | 3,432 | 3,535 | 3,641</li>
    <li>THYROXINE, TOTAL — 1,950 | 2,575 | 2,652 | 2,732 | 2,814</li>
    <li>TROPONIN I CARDIAC — 2,855 | 4,438 | 4,571 | 4,708 | 4,849</li>
    <li>HEPATITIS B SURFACE AG — 3,435 | 5,633 | 5,802 | 5,976 | 6,155</li>
    <li>HEPATITIS B SURFACE AB — 3,848 | 6,485 | 6,680 | 6,880 | 7,086</li>
    <li>HEPATITIS B CORE AB TOTAL — 3,522 | 5,183 | 5,339 | 5,500 | 5,665</li>
    <li>HEPATITIS C AB — 3,193 | 5,136 | 5,290 | 5,449 | 5,613</li>
    <li>HEPATITIS A IGM — 2,675 | 4,068 | 4,190 | 4,316 | 4,446</li>
    <li>HEPATITIS A AB, TOTAL — 2,964 | 4,663 | 4,803 | 4,947 | 5,095</li>
    <li>RUBELLA VIRUS IGG — 1,724 | 2,108 | 2,171 | 2,236 | 2,303</li>
    <li>HBA1C-IFCC, NGSP — 4,668 | 8,173 | 8,418 | 8,671 | 8,931</li>
    <li>PRO-BNP — 2,322 | 3,341 | 3,441 | 3,544 | 3,650</li>
  </ol>

  <p><strong>Agency and Requirement Description and Market Research Conducted</strong></p>
  <p>DHA HCD-SD is supporting Brian D. Allgood Army Community Hospital in South Korea, with a requirement for Chemistry/Immunology Reagents with Analyzer. Specifically, this requirement is for tests in the product list above.</p>
  <p>Extensive market research through the General Services Administration (GSA), Federal Supply Schedules (FSS), or other mandatory sources. Broad database searches were conducted across FPDS-NG, GSA Advantage, GSA eLibrary, GSA Global Supply, NASA SEWP, and VA FSS using keywords such as “Chemistry”. These searches either yielded zero results or failed to identify contractors capable of providing the exact or equal supplies required. Additionally, a review of internal contracting activity via the BPA Tracker revealed no similar contracts currently in place to leverage. Open market research, including internet searches and personal telephone contacts with potential vendors, confirmed that while "Chemistry/Immunology Reagents/Analyzers" are commercially available RFO 12.102(b) only Ortho Clinical Diagnostics Singapore PTE LTD, Korea Branch is the only vendor that can meet the agency's requirements.</p>

  <p><strong>Delivery Location</strong></p>
  <p>BRIAN D. ALLGOOD ARMY COMMUNITY HOSPITAL<br />
  348TH QM CO SRA BLDG<br />
  1603 CAMP HUMPHREYS PYEONGTAEK, 17982</p>

  <p><strong>Estimated Delivery Schedule:</strong> 1 April 2027 to 30 September 2031 (Including a 6 month base period and four (4) 12 month option years).</p>

  <p>Based on market research and previous acquisition history, it has been determined that Ortho Clinical Diagnostics Singapore PTE LTD, Korea Branch, is the only source that can meet the Government’s minimum requirements to provide chemistry/immunology reagents and analyzer for the Brian D. Allgood Army Community Hospital.</p>

  <p>This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the chemistry/immunology reagents and analyzer for the Brian D. Allgood Army Community Hospital. Capability statements shall not exceed two (2) (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.</p>

  <p>If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Contract Specialist Susan Fujita at susan.m.fujita.civ@health.mil and Contracting Officer Cha-on P. Gordon at cha-on.p.gordon2.civ@health.mil. The closing date for challenges is no later than 11:00 a.m. (Hawaii Time), Thursday December 3, 2026.</p>

  <p><strong>NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.</strong></p>
</div>

[View original listing](https://sam.gov/opp/bf19497f9cfc4dc4855e9bbc6a1848ae/view)
